Ceribell (NASDAQ: CBLL) saw its stock price surge 5.04% in after-hours trading on Tuesday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.
The medical technology company reported quarterly revenue of $21.2 million, surpassing analyst expectations of $20.528 million by 3.27%. Ceribell also posted a narrower-than-expected loss per share of $(0.38), beating the consensus estimate of $(0.40) by 4.52%.
Adding to the positive sentiment, Ceribell raised its 2025 revenue guidance to a range of $85-$88 million, signaling strong confidence in its growth trajectory. This combination of better-than-expected current performance and improved future outlook appears to be driving investor enthusiasm, resulting in the significant after-hours stock price increase.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。